Department of Critical Care Medicine, University-Town Hospital of Chongqing Medical University, Chongqing, China.
Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Bioengineered. 2021 Dec;12(2):10823-10836. doi: 10.1080/21655979.2021.1967035.
To verify whether Ang-(1-7) produces an antagonistic effect on Ang II-mediated atrial remodeling. Ang II-induced HL-1 cell model and a rat model of Ang II-induced atrial remodeling were constructed and intervened with Ang II Ang-(1-7), AngII +Ang-(1-7), Ang II+ c-Src specific inhibitor (SU6656), and Ang II + Ang-(1-7) + SSG (SHP-1/2 specific inhibitor, stibogluconate), respectively. The systolic blood pressure of the rat caudal artery was detected. And trial fibrosis was detected by Picrosirius red staining and Masson's trichrome staining. Expressions of transforming growth factor-β (TGF-β), tissue inhibitor of metalloproteinases 1 (TIMP1), Matrix metalloproteinase 2 (MMP-2), connective tissue growth factor (CTGF), galectin-3, α-smooth muscle actin (α-SMA), and collagen I/III were subjected to qPCR and western blot. Furthermore, SHP-1 binding to c-Src was verified by co-immunoprecipitation (Co-IP). Results showed that the expressions of TGF-β, TIMP1, MMP-2, CTGF, α-SMA, galectin-3, and collagen I were increased markedly in the Ang II intervention group, and the expressions of p-ERK1/2, p-Akt, and p-p38MAPK were also increased dramatically. Ang-(1-7) or SU6656 addition could inhibit the action of Ang II factor, thereby minimizing the expressions of the previously described genes and proteins. Simultaneously, SSG supplement reversed the antagonistic effect of Ang-(1-7) on Ang II, and the latter elevated the blood pressure and induced atrial fibrosis in rats. Ang-(1-7) could reverse the changes related to Ang II-induced atrial fibrosis in rats. In conclusion, Ang-(1-7) antagonized Ang II-induced atrial remodeling by regulating SHP-1 and c-Src, thereby affecting the MAPKs/Akt signaling pathway.
为了验证血管紧张素(1-7)(Ang-(1-7))是否对血管紧张素 II(Ang II)介导的心房重构产生拮抗作用。构建了 Ang II 诱导的 HL-1 细胞模型和 Ang II 诱导的心房重构大鼠模型,并分别用 Ang II、Ang-(1-7)、Ang II + Ang-(1-7)、Ang II + c-Src 特异性抑制剂(SU6656)和 Ang II + Ang-(1-7)+SSG(SHP-1/2 特异性抑制剂,葡庚糖酸钠)进行干预。检测大鼠尾动脉的收缩压。并用苦味酸天狼猩红染色和 Masson 三色染色检测试验性纤维化。采用 qPCR 和 Western blot 检测转化生长因子-β(TGF-β)、金属蛋白酶组织抑制剂 1(TIMP1)、基质金属蛋白酶 2(MMP-2)、结缔组织生长因子(CTGF)、半乳糖凝集素-3、α-平滑肌肌动蛋白(α-SMA)和胶原 I/III 的表达。此外,通过免疫共沉淀(Co-IP)验证 SHP-1 与 c-Src 的结合。结果表明,Ang II 干预组 TGF-β、TIMP1、MMP-2、CTGF、α-SMA、半乳糖凝集素-3 和胶原 I 的表达明显增加,p-ERK1/2、p-Akt 和 p-p38MAPK 的表达也明显增加。加入 Ang-(1-7)或 SU6656 可抑制 Ang II 因子的作用,从而使上述基因和蛋白的表达最小化。同时,SSG 补充剂逆转了 Ang-(1-7)对 Ang II 的拮抗作用,后者使大鼠血压升高并诱导心房纤维化。Ang-(1-7)可逆转 Ang II 诱导的大鼠心房纤维化相关变化。结论:Ang-(1-7)通过调节 SHP-1 和 c-Src 拮抗 Ang II 诱导的心房重构,从而影响 MAPKs/Akt 信号通路。